Home › Research › Treatments
Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs
Ashvin Varadharajan, Aarjith Damian Davis, Aishwarya Ghosh, Tejaswini Jagtap, Anjo Xavier, Anjana Jayakumar Menon, Dwaiti Roy, Sandhya Gandhi et al.. Journal of neurosciences in rural practice, 2023-10-07
Topic: Drug trials: efficacy and safety
Plain-language summary
Both act by binding with fibrillary conformations of Aβ plaques in the brain. These drugs have a risk of causing amyloid-related imaging abnormalities, especially in persons with ApoE4 gene. Aducanumab is administered once every 4 weeks and lecanemab once every 2 weeks. The decision on the choice of the drug must be made after considering the availability of drug, compliance of patient (once-daily vs. multiple doses daily), cost, specific comorbidities, and the risk-benefit ratio for the particular patient. Other non-pharmacological treatment modalities must also be adopted to have a holistic approach toward the treatment of AD.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Varadharajan, A., Davis, A. D., Ghosh, A., Jagtap, T., Xavier, A., Menon, A. J., et al. (2023). Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs. Journal of neurosciences in rural practice. https://doi.org/10.25259/jnrp_356_2023
Vancouver
Varadharajan A, Davis AD, Ghosh A, Jagtap T, Xavier A, Menon AJ, et al. Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs. Journal of neurosciences in rural practice. 2023. doi:10.25259/jnrp_356_2023. PMID: 38059250.
BibTeX
@article{varadharajan2023-38059250,
author = {Varadharajan, Ashvin and Davis, Aarjith Damian and Ghosh, Aishwarya and Jagtap, Tejaswini and Xavier, Anjo and Menon, Anjana Jayakumar and Roy, Dwaiti and Gandhi, Sandhya and others},
title = {{Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs}},
journal = {Journal of neurosciences in rural practice},
year = {2023},
doi = {10.25259/jnrp_356_2023},
pmid = {38059250},
url = {https://doi.org/10.25259/jnrp_356_2023}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Both act by binding with fibrillary conformations of Aβ plaques in the brain.
- These drugs have a risk of causing amyloid-related imaging abnormalities, especially in persons with ApoE4 gene.
- Aducanumab is administered once every 4 weeks and lecanemab once every 2 weeks.
- The decision on the choice of the drug must be made after considering the availability of drug, compliance of patient (once-daily vs. multiple doses daily), cost, specific comorbidities, and the risk-benefit ratio for the particular patient.
- Other non-pharmacological treatment modalities must also be adopted to have a holistic approach toward the treatment of AD.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 41/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 23 of the 56 points we could judge it on, which is 41 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Journal of neurosciences in rural practice) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2023 — within 6 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38059250) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 23 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 23 of the 56 points we could judge it on is 41 out of 100. |
| Total | 41 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “monoclonal”
332 studies in the library carry the topic tag “monoclonal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 332 tagged studies.